Nucelion Therapeutics, Pandorum Technologies to take up 2 ophthalmology projects

SENSEX 73,043.01

 -555.66

NIFTY 22,616.80

 -132.95

CRUDEOIL 9,674.00

+ 176.00

GOLD 143,575.00

 -563.00

SILVER 195,278.00

 -1,439.00

SENSEX 73,043.01

 -555.66

NIFTY 22,616.80

 -132.95

NIFTY 22,616.80

 -132.95

CRUDEOIL 9,674.00

+ 176.00

CRUDEOIL 9,674.00

+ 176.00

GOLD 143,575.00

 -563.00

'; } document.getElementById("lgdv").innerHTML = htmlElements; } function numberformat(i) { return Number(parseFloat(i).toFixed(2)).toLocaleString('en', { minimumFractionDigits: 2 }) } async function gatherResponse(response) { const { headers } = response; const contentType = headers.get('content-type') || ''; if (contentType.includes('application/json')) { return await response.json() } return response.text(); } function getWidth() { if (Math.max(document.body.scrollWidth,document.documentElement.scrollWidth,document.body.offsetWidth,document.documentElement.offsetWidth,document.documentElement.clientWidth) > 991) { document.getElementById("mob").style.display = "none"; document.getElementById("lgdv").style.display = "block"; } else { document.getElementById("mob").style.display = "block"; document.getElementById("lgdv").style.display = "none"; } } getWidth(); THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.

The two projects will focus on developing investigational therapies for advanced keratopathy and wet age-related macular degeneration (wet AMD)

By BL Hyderabad Bureau

Updated - October 28, 2026 at 11:41 AM. | Hyderabad, Oct 28

The two projects have a combined planned outlay of about ₹17 crore, comprising up to ₹8 crore in funding under the Centre’s Promotion of Research and Innovation in Pharma Medtech (PRIP) scheme | Photo Credit: Vladislav Stepanov

Nucelion Therapeutics, a gene therapy CDMO and an arm of Bharat Biotech, and Pandorum Technologies, a tissue engineering and regenerative medicine company, will take up two ophthalmology projects focused on developing investigational therapies for advanced keratopathy and wet age-related macular degeneration (wet AMD).

Bengaluru-based Pandorum is developing cell-free regenerative medicines based on designer exosomes that carry biological signals involved in communication between cells. Through its collaboration with Nucelion, Pandorum is connecting programmable regenerative-medicine design with reproducible manufacturing and indication-specific development — while building that capability in India with national research support.

Hyderabad-based Nucelion’s role in the two investigational ophthalmology projects will centre on process development and manufacturing support for Pandorum’s designer exosomes, aligned with the requirements and development stage of each programme. 

The broader Pandorum–Nucelion collaboration is intended to provide material manufactured under Good Manufacturing Practice (GMP) for clinical studies in India and abroad, subject to applicable regulatory approvals.

The advanced-keratopathy programme by Pandorum is directed towards clinical evaluation of investigational therapies for severe corneal disease. 

The two projects have a combined planned outlay of about ₹17 crore, comprising up to ₹8 crore in funding under the Centre’s Promotion of Research and Innovation in Pharma Medtech (PRIP) scheme, according to a release. 

Published on October 28, 2026

THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.Sign into Unlock benefits!

• Access 10 free stories per month
• Get notified by email for early preview to new features, discounts & offers